

## GP Update on Implementation of NICE TAs 393 and 394

Alirocumab and Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia

The East Kent Prescribing Group approved NICE implementation guidance for these drugs in April 2017 [Alirocumab & Evolocumab guidance](#).

At this time GPs were advised to make referrals for eligible patients to East Kent Hospitals NHS Foundation Trust endocrinology team. However we have been recently informed by EKHFT that currently they do not have sufficient endocrinologists to provide this service. We have been given assurance that there are plans being developed to enable the service to be provided locally.

In the interim, until a local service is available, eligible patients requiring assessment for treatment should be referred to one of the lipid clinics at Medway Maritime NHS Foundation Trust (lead consultant Dr Rochin Patle) or Maidstone and Tunbridge Wells NHS trust (lead consultant Dr Supriya Joshi).

**Approved by:** East Kent Prescribing Group (Representing Ashford CCG, Canterbury and Coastal CCG, South Kent Coast CCG and Thanet CCG)

**Date:** Nov 2017

**Address:** c/o Canterbury and Coastal CCG, Ground Floor, Council Offices, Military Road, Canterbury, Kent, CT1 1YW

**Contact:** T: 01227 791267 | E: [accg.eastkentprescribing@nhs.net](mailto:accg.eastkentprescribing@nhs.net)